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What does this article add to our knowledge? Prevalence of penicillin allergy registration in a general population of
patients hospitalized in a Dutch University Medical Center is 5.6%, has high impact on antibiotic prescribing, and is
associated with a higher risk of readmission within 12 weeks.
How does this study impact current management guidelines? Veriﬁcation of the penicillin allergy in hospitalized
patients might restrict the use of reserve antibiotics and improve patient outcome.BACKGROUND: Suspected penicillin allergy (Pen-A) is often
not veriﬁed or excluded by diagnostic testing.
OBJECTIVE: To assess the prevalence and impact of Pen-A
registration in a Dutch University Medical Center.
METHODS: In a prospective matched cohort study, all
admitted patients (July 2013-July 2014) who underwent a
pharmacotherapeutic interview were selected. Patients with a
registered Pen-A were matched on age, sex, and department of
admission with up to 3 patients without a registered Pen-A.
Relative risks (RRs) of receiving a reserve antibiotic, death
during hospitalization, and rehospitalization were compared in
the 2 cohorts. The number and type of antibiotics prescribed
during admission and duration of hospitalization were
compared.
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926patients had a higher risk of receiving reserve antibiotics (RR,
1.38; 95% CI, 1.22-1.56) and of being rehospitalized within 12
weeks (RR, 1.28; 95% CI, 1.10-1.49). A signiﬁcantly larger
proportion of Pen-A registered patients received reserve antibi-
otics such as tetracyclines (1.8% vs 0.8%), macrolides/lincosa-
mides/streptogramins (12.5% vs 4.9%), and quinolones (7.9% vs
4.3%) or received 2 or more types of antibiotics during hospi-
talization (21.7% vs 16.9%).
CONCLUSIONS: Prevalence of Pen-A registration in hospital-
ized patients is high, has high impact on antibiotic prescribing,
and is associated with a higher risk of readmission. Veriﬁcation
of the Pen-A in hospitalized patients might restrict the use of
reserve antibiotics and improve patient outcome.  2016 The
Authors. Published by Elsevier Inc. on behalf of the American
Academy of Allergy, Asthma & Immunology. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (J Allergy Clin
Immunol Pract 2016;4:926-31)
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Antibiotics are one of the most frequently prescribed type of
drugs, of which beta-lactam antibiotics account for the most.1-3
Beta-lactam antibiotics are characterized by their high safety
proﬁle, narrow spectrum of activity, and low costs. One of the
main factors limiting their use is the suspicion of penicillin al-
lergy (Pen-A).4 Pen-A is the most commonly registered drug
allergy,5-7 but the true prevalence in the general population is
unknown, and remains difﬁcult to determine because of varying
study populations and designs. A Danish study reported a
prevalence of 5% in hospitalized patients, whereas studies from
the United States report higher prevalences of up to 16%.5,8-12 A
recent study performed in a Dutch general practice population in
which Pen-A registration in medical ﬁles was assessed reported a
prevalence of 2%.13
Diagnostic workup for evaluation of Pen-A may include
detailed patient history, skin testing, in vitro testing, and drug
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ATC- Anatomical Therapeutic ChemicalPen-A- penicillin allergy
RR- relative riskUMCU-University Medical Center Utrechtchallenge. Studies on outpatient adult patients showed that an
alleged Pen-A can be conﬁrmed in only a minority (16.5%-
29.0%) of patients.6,9,10,14-20 This percentage of conﬁrmed Pen-
A seems lower in children than in adults (7.9%-15.9%) and also
lower in hospitalized patients when compared with outpatients.
In patients with a history of possible Pen-A who are admitted to
hospitals, the prevalence of conﬁrmed allergy varies from 1% to
14 %.21-25 Altogether, most patients with a suspected Pen-A are
not currently allergic and should tolerate penicillin antibiotics.
In clinical practice, hospitalized patients with a documenta-
tion of penicillin antibiotic allergy are more often treated with
reserve antibiotics such as ﬂuoroquinolones, macrolides, glyco-
peptides, vancomycin, and aminoglycosides.5,11,12 Use of these
reserve antibiotics has been associated with a higher risk of
treatment failure, adverse drug reactions, complications such as
Clostridium difﬁcile infection, methicillin-resistant Staphylococcus
aureus infection, and vancomycin-resistant Enterococcus in-
fections, and higher costs and reinforce the development of
antibiotic resistance.4,5,7-10,26-29
Recent studies showed that patients with a Pen-A registration
have a longer duration of hospitalization than do patients
without this registration.5,12 However, evidence on these various
consequences of registered Pen-A was based mostly on very small
patient numbers and poorly designed studies.4,5,7,10,11
This study aimed to assess the prevalence of registered Pen-A
in a large Dutch tertiary university medical hospital center and its
impact on health careerelated factors such as the number and
type of antibiotics prescribed, mortality during hospitalization,
duration of hospital stay, and risk of readmission.
METHODS
Setting and study population
This prospective, matched cohort study included patients from
the Utrecht Patient Orientated Database, which includes all patients
treated at the University Medical Centre in Utrecht (UMCU), a
university hospital in the Netherlands with 1042 beds. All patient
data are electronically registered and anonymized.30 This study was
approved by the local medical research ethical committee (METC
14-626/C).
The source population included all patients admitted to the
UMCU (N ¼ 24,165) from July 1, 2013, until July 1, 2014. A
systematic standardized pharmacotherapeutic interview was intro-
duced in 2010 for all patients admitted to the UMCU and is per-
formed by a trained nurse or pharmacist assistant before admissions
or at patient bedside within 24 hours of admission of all patients
unselectively. The study population included all patients (children
and adults) who underwent a standardized pharmacotherapeutic
interview for evaluation and registration of drug usage and drug
hypersensitivity. If patients report a drug allergy, the following
criteria for registration of drug hypersensitivity are used by the
trained nurse or pharmacist assistant: (1) evaluation by a specialist or
general practitioner and/or (2) symptoms of cutaneous reactions,
dyspnea, collapse, or fever after drug exposure up to a few days. Drughypersensitivity is registered in the patients electronical medical ﬁle.
This registration can be updated by physicians at any time. There is
no standardized recommendation on how to deal with a drug allergy
registration.
The study population excluded patients admitted to intensive care
wards, patients admitted for day treatments, patients admitted and
discharged during the same weekend, and healthy women admitted
because of labor and neonates, because the standardized pharma-
cotherapeutic interview was not implemented reliably for these pa-
tients in the study period.
Patient cohort
Patients with a registered Pen-A (Pen-A patients) in their medical
journal during their ﬁrst admission during the study period (index
date) were matched with up to 3 patients who had no Pen-A
registered in their medical ﬁle (nonePen-A patients) on the index
date. Penicillin is deﬁned as all class Anatomical Therapeutic
Chemical (ATC)-J01C penicillin beta-lactam antibiotics including
among others ampicillin and amoxicillin.31 Registered Pen-A pa-
tients were matched to nonePen-A patients on sex, age up to  3
years, and department of admission.
Study outcomes
The primary outcome measure of this study was prevalence of
Pen-A registration. The secondary aim was to compare the risk of the
ﬁrst antibiotic prescribed during admission being a reserve antibiotic,
the risk of death during hospitalization, and assessing the number,
type, and route (intravenous) of antibiotics prescribed during
admission and duration of hospitalization (in days) in patients with
and without a Pen-A. In addition, the risk of readmission within 4
and 12 weeks from discharge was assessed.
Duration of hospitalization was deﬁned as 1 day plus the date of
discharge minus the date of admission. Prescribed antibiotics were
grouped into the following 10 ATC classes: tetracyclines (J01A);
amphenicols (J01B); beta-lactam antibacterials, penicillins (J01C);
other beta-lactam antibacterials (J01D); sulfonamides and trimeth-
oprim (J01E); macrolides, lincosamides, and streptogramins (J01F);
aminoglycoside antibacterials (J01G); quinolone antibacterials
(J01M); combinations of antibacterials (J01R); and other antibac-
terials (J01X).31 Reserve antibiotics were deﬁned as all ATC groups
excluding penicillins (J01C).STATISTICAL ANALYSIS
Prevalence was measured by deﬁning the number of patients
with a registered Pen-A in the study population. Descriptive
statistics for the matched cohort were reported using pro-
portions, medians, and interquartile ranges. The associations
between having a Pen-A registration and receiving a reserve
antibiotic as a ﬁrst prescription during hospitalization, mor-
tality during hospitalization, and rehospitalization within 4
weeks and 12 weeks after discharge were estimated as relative
risk (RR) with 95% CI using stratiﬁed Cox proportional haz-
ards analysis. Differences in proportion were assessed for the
type of antibiotics prescribed during hospitalization, receiving 2
or more antibiotics, and receiving antibiotics through intrave-
nous administration using Mantel-Haenszel chi-square test.
Medians were compared using Mann Whitney tests. Differ-
ences were considered statistically signiﬁcant when the P value
was less than .05. All statistical analyses were conducted with
SAS9.4.
TABLE I. Baseline characteristics of patients with and without
Pen-A registration
Characteristic
No. of patients (%)
Registered
Pen-A patients
(n [ 997)
NonePen-A
patients
(n [ 2939)
Age (y), median (IQR) 55.5 (37-68) 55.0 (37-68)
Sex: female, n (%) 666 (66.8) 1957 (66.6)
Specialism of admission, n (%)
Surgery 262 (26.3) 772 (26.3)
Internal medicine 144 (14.4) 380 (12.9)
Small surgical specialisms* 127 (12.7) 406 (13.8)
Cardiovascular 87 (8.7) 258 (8.8)
Gynaecology & obstetrics 82 (8.2) 242 (8.2)
Urology 66 (6.6) 127 (4.3)
Neurology/psychiatry 60 (6.0) 194 (6.6)
Oncology 38 (3.8) 139 (4.7)
Pediatrics 36 (3.6) 124 (4.2)
Gastroenterology 31 (3.1) 102 (3.5)
Nephrology 27 (2.7) 81 (2.8)
Geriatrics 14 (1.4) 43 (1.5)
Dermatology 12 (1.2) 49 (1.7)
Supportive departments† 11 (1.1) 22 (0.7)
*Oral surgery, dental medicine, otolaryngology, and ophthalmology.
†Anesthesia, pain team, nuclear radiology, radiology, radiotherapy, and pathology.
TABLE II. Antibiotic prescribing and health care use during
hospitalization
Treatment
No. of patients (%)
Registered
Pen-A patients
(n [ 997)
NonePen-A
patients
(n [ 2939) P value*
Duration of hospitalization
(d), median (IQR)
4.0 (2.0-8.0) 4.0 (2.0-8.0) .80
Antibiotic prescribing during
hospitalization, n (%)
No antibiotic use 543 (54.5) 1749 (59.5) <.01
Tetracycline (J01A) 18 (1.8) 24 (0.8) <.01
Beta-lactam antibacterials
(J01C)
66 (6.6) 391 (13.3) <.01
Nonpenicillin beta-lactam
antibacterial (J01D)
283 (28.4) 741 (25.2) .03
Sulfonamides and
trimethoprim (J01E)
55 (5.5) 139 (4.7) .29
Macrolides, lincosamides,
& streptogramines
(J01F)
125 (12.5) 144 (4.9) <.01
Aminoglycosides (J01G) 23 (2.3) 57 (1.5) .44
Quinolones (J01M) 79 (7.9) 127 (4.3) <.01
Other antibacterials (J01X) 101 (10.1) 228 (7.8) <.01
2 antibiotics 216 (21.7) 496 (16.9) <.01
Intravenous administration 350 (35.1) 946 (32.2) .06
*Mantel-Haenszel c2 test for differences between registered Pen-A patients and
nonePen-A patients.
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Characteristics of the study population
A total of 17,959 patients (50.2% women; median age, 51.0
years) admitted underwent a pharmacotherapeutical interview.
Of these, 1010 patients (5.6%) had a Pen-A registration (66.8%
women; median age, 55.5 years, interquartile range, 37-68), of
which 997 (98.7%) could be matched with at least 1 patient
without a Pen-A registration. A total of 962 registered Pen-A
patients were matched to 3 nonePen-A patients, 18 registered
Pen-A patients were matched to 2 nonePen-A patients, and 17
registered Pen-A patients were matched to 1 nonePen-A patient
(Table I).
Antibiotic treatment
A total of 2292 (58.2%) patients (Pen-A and nonePen-A
patients) did not receive antibiotic treatment during admission
(54.5% of registered Pen-A patients vs 59.5% of nonePen-A
patients), whereas 1644 patients (41.8%) received 1 or more
antibiotic (Table II). Most of the patients who did receive
antibiotic treatment got monotherapy (n ¼ 932 [57.6%]).
Pen-A registered patients had a higher risk of receiving a
reserve type of antibiotic as a ﬁrst antibiotic prescription on
admission (RR, 1.38; 95% CI; 1.22-1.56). When analyzing the
speciﬁc types of antibiotics, a statistically signiﬁcant higher
proportion of Pen-A registered patients received tetracycline,
nonpenicillin beta-lactam antibacterials, macrolides/lincosa-
mides/streptogramins, quinolones, or other antibacterials when
compared with patients without a Pen-A registration (Table II).
Also, a signiﬁcantly higher proportion of patients with a Pen-A
registration were prescribed 2 or more antibiotics during hospi-
talization (21.7% vs 16.9%). There was no signiﬁcant difference
in the proportion of patients receiving sulfonamides or
trimethoprim or aminoglycosides. As to be expected, a lower
proportion of patients with a Pen-A registration got a penicillin
beta-lactam antibiotic prescribed compared with patients without
a Pen-A registration. Interestingly, 14.5% (n ¼ 66) of all regis-
tered Pen-A patients, treated with antibiotics, were exposed to
penicillin beta-lactam antibiotics despite their Pen-A registration.
The ranking and percentages of frequency of speciﬁc antibiotic
prescription differed in patients with and without a Pen-A
registration (Table III).
Other outcomes
Duration of hospitalization did not differ statistically between
patients with and without a Pen-A registration and ranged from
1 day to 195 days, with a median duration of 4.00 days (inter-
quartile range, 2.00-8.00). Mortality during hospitalization was
not signiﬁcantly different between patients with (1.2%) and
without (1.0%) Pen-A registration (RR, 1.49; 95% CI, 0.58-
3.85). There was no signiﬁcant difference in the risk of read-
mission within 4 weeks after discharge between patients with
(18.3%) and without (15.1%) Pen-A registration (RR, 1.19;
95% CI, 0.98-1.44). The RR of readmission within 12 weeks
after discharge was signiﬁcantly higher in patients with (27.0%) a
Pen-A registration (RR, 1.28; 95% CI, 1.10-1.49) than in pa-
tients without a Pen-A registration (21.9%).
DISCUSSION
This is the ﬁrst study in Europe investigating the prevalence
and impact of Pen-A registration in hospitalized patients and
shows a prevalence of 5.6% in this Dutch tertiary medical center.These patients have a signiﬁcantly higher risk of receiving a
reserve antibiotic of a broad-spectrum type than do patients
without a Pen-A registration. They received more often antibi-
otics during hospitalization and when treated with antibiotics, a
TABLE III. Top 10 antibiotics (chemical substance) used by registered Pen-A and nonePen-A patients
S. no. Registered Pen-A patients (N [ 997) NonePen-A patients (N [ 2939)
1 Cefazolin: n ¼ 156 (21.4%) Cefazolin: n ¼ 481 (26.8%)
2 Ceftriaxone: n ¼ 75 (10.3%) Amoxicillin and enzyme inhibitor: n ¼ 252 (14.0%)
3 Clindamycin: n ¼ 67 (9.2%) Ceftriaxone: n ¼ 162 (9.0%)
4 Metronidazole: n ¼ 57 (7.8%) Metronidazole: n ¼ 147 (8.2%)
5 Ciproﬂoxacin: n ¼ 47 (6.4%) Ciproﬂoxacin: n ¼ 97 (5.4%)
6 Sulfamethoxazole and trimethoprim: n ¼ 36 (4.9%) Sulfamethoxazole and trimethoprim: n ¼ 96 (5.3%)
7 Amoxicillin and enzyme inhibitor: n ¼ 32 (4.4%) Clindamycin: n ¼ 72 (4.0%)
8 Azithromycin: n ¼ 25 (3.4%) Flucloxacillin: n ¼ 60 (3.3%)
9 Erythromycin: n ¼ 22 (3.0%) Cefuroxime: n ¼ 43 (2.4%)
10 Cefuroxime: n ¼ 21 (2.9%) Tobramycin: n ¼ 37 (2.1%)
Multiple prescriptions of the same antibiotic during hospitalization were counted only once.
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biotics, especially reserve antibiotics such as macrolides, clinda-
mycin, quinolones, and tetracyclines when compared with
patients without Pen-A registration. Furthermore, patients with
Pen-A registration have a higher risk of readmission within 12
weeks.
In this study, the prevalence of Pen-A registration is based on
systematically performed standardized pharmacotherapeutic in-
terviews, which strongly reduces potential recall bias and in-
creases reliability, by fewer registration of adverse effects of
antibiotics as an allergic reaction to antibiotics. We observed a
lower prevalence of registered Pen-A than reported in earlier
studies from the United States5,10-12 and the United Kingdom,8
which range from 11.2% to 15.6%. These differences might
partly be explained by the effect of a reliable pharmacother-
apeutic interview in our study. Difference in prevalence might
also be inﬂuenced by the study design and type of populations
because higher prevalences (up to 15.6%) were shown in studies
investigating populations with antibiotic need only.10-12 Another
explanation of differences in the prevalence of documented Pen-
A between these countries might be the difference in antibiotic
use in the speciﬁc population. Dutch guidelines for the use of
antibiotics advise prudent antimicrobial prescribing,32 resulting
in a low deﬁned daily dosage of 8.9 per 1000 people per day of
antibiotics in the Netherlands compared with the United States
(deﬁned daily dosage of 25 per 1000 people per day).2,33,34 A
recent small Danish study on 3642 patients supports this hy-
pothesis with a low prevalence of suspected Pen-A of 5% in a
university hospital population and a low deﬁned daily dosage in
Denmark (11.3 per 1000 people per day).2,9
Our study shows that the treatment of hospitalized patients is
highly inﬂuenced by the “Pen-A” registration. When receiving
antibiotics, signiﬁcantly larger proportions of patients with Pen-
A registration are treated with macrolides and clindamycin,
quinolones, and tetracyclines, suggesting that these antibiotics
are used as reserve antibiotics. These reserve antibiotics are
known for higher costs and more adverse reactions and are more
likely to induce resistance compared with beta-lactam penicil-
lins.35,36 Increased usage of macrolides and clindamycin, quin-
olones, and tetracyclines in patients with Pen-A registration was
also shown in studies from Israel, the United States, and the
United Kingdom.4,5,7,11 However, these studies also demon-
strated vancomycin as a reserve antibiotic, which is signiﬁcantly
more often used in patients with suspected allergy for penicillin
antibiotics.4,5,7,11 In the Netherlands, the prevalence ofmethicillin-resistant Staphylococcus aureus infection is low,
explaining the very low (n ¼ 39 [1.5%]) frequency of vanco-
mycine usage in our study population, without signiﬁcant dif-
ference between cases and control subjects.37
Studies from the United States found a signiﬁcantly increased
duration of hospitalization for patients with a Pen-A registration
compared with control subjects.5,12 This ﬁnding was not
conﬁrmed in our study. However, the other studies differed from
ours in design because the cumulative duration of hospitalization
days included the index admission and all readmissions during
the study period.
We did not ﬁnd a signiﬁcant difference in the risk of read-
mission within 4 weeks in those with and without Pen-A. This is
in line with results of the study by Charneski et al12 who
investigated the relation between Pen-A registration and read-
mission within 4 weeks of hospital discharge and found no as-
sociation between Pen-A registration and frequency of
readmission. When we assessed the risk of readmission within 12
weeks after discharge, we found this to be signiﬁcantly higher in
patients with Pen-A registration. So far, this study is the ﬁrst
study that reports a signiﬁcantly higher risk of readmissions for
patients with a Pen-A registration. This higher risk of read-
mission might be a secondary result of treatment with second-
choice antibiotics, but more research is needed to explain this
observation.38
We observed no difference in mortality between patients with
registered Pen-A and those without. However, a 1.6-fold
increased risk of mortality during admission in patients with
this allergy registration compared with controls was reported in a
study from the United States by Charneski et al.12 Further
research is needed to investigate whether mortality is inﬂuenced
by Pen-A registration.
The main strengths of this study are the systematically per-
formed standardized pharmacotherapeutic interviews, reliable
statistical analysis, and the high number of patients evaluated.
However, the study also has several limitations. Patients without
pharmacotherapeutic interviews were excluded, including pa-
tients from the intensive care unit, a population that is of high
interest. Furthermore, although patients with and without Pen-A
registration were matched on the department of admission, other
factors such as medical diagnosis, disease severity, or the number
of drug allergies that also might inﬂuence the antibiotic treat-
ment and risk of readmission could not be considered. However,
because we presume that only approximately 20% or less of the
patients with Pen-A registration are truly allergic, we expect the
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should be conﬁrmed in an additional study. Lack of details of the
registered patients’ reactions is another limitation of the study.
Our study shows that Pen-A registration has a high impact on
treatment and the risk of readmission in hospitalized patients.
Several studies have demonstrated that in patients with suspected
Pen-A this diagnosis is excluded by allergological workup in the
vast majority of patients.9,15-20 We therefore can assume that in
most hospitalized patients with Pen-A registration the prescribing
of beta-lactam antibiotics is wrongfully avoided and patients are
unnecessarily strained by the subsequent disadvantages.
Antimicrobial resistance is widely considered as one of the
major risks to the global society and is among others caused by
inappropriate use of available antibiotics such as unnecessary use
of second-choice antibiotics.39 Integration of antibiotic allergy
management into the decision support systems of antimicrobial
stewardship programs might represent an opportunity to restrict
the use of reserve antibiotics and the subsequent risk of anti-
microbial resistance for the individual patient and the society.
Several studies have shown that active antibiotic allergy veri-
ﬁcation by skin testing and drug challenge results in reduction in
the use of reserve antibiotics.25,40,41 However, further studies are
needed to investigate whether exclusion of Pen-A more consis-
tently can bring antibiotic use and risk of readmission in patients
with Pen-A registration back in line with those seen in patients
without Pen-A registration.
In conclusion, this study shows a 5.6% prevalence of Pen-A
registration in hospitalized patients in a Dutch tertiary medical
center. Pen-A registration in hospitalized patients has a high
impact on antibiotic treatment strategies, including higher risk
for prescribing broad-spectrum antibiotics and increased risk of
readmission within 12 weeks of discharge. Further studies are
needed to investigate whether better veriﬁcation of Pen-A does
improve policy in antibiotic treatment in these patients.REFERENCES
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